Product Overview

Glycomet GP 2 is a prescription combination tablet that contains two well‑studied antidiabetic agents, metformin and glimepiride, formulated in a sustained‑release (sr) strength of 500 mg + 2 mg. Manufactured by USV Pvt Ltd, the product is packaged as 15 tablets per strip and is available in pack sizes of 30, 60, and 90 tablets. It is specifically indicated for the management of Type 2 diabetes mellitus when lifestyle modifications alone are insufficient to achieve adequate glycaemic control. The medication is designed to provide consistent plasma concentrations over an extended period, reducing the frequency of dosing and supporting better adherence.

What is Glycomet GP 2

Glycomet GP 2 belongs to the class of oral hypoglycaemic agents used in diabetes care. Metformin works primarily by decreasing hepatic glucose production and improving insulin sensitivity, while glimepiride stimulates pancreatic beta‑cells to release insulin, thereby lowering fasting and post‑prandial blood glucose levels. The combination leverages the complementary mechanisms of these two drugs to achieve a more pronounced reduction in overall glucose excursions compared with either agent used alone. The sustained‑release formulation ensures a gradual release of the active ingredients, which helps maintain steady therapeutic levels throughout the day.

Uses and Benefits

The primary use of Glycomet GP 2 is the pharmacologic treatment of Type 2 diabetes when diet, exercise, and other oral agents have not provided adequate glycaemic control. Clinical studies have demonstrated that the combination can lead to a lower hemoglobin A1c (HbA1c) by up to 1–1.5 % when used as part of a comprehensive diabetes management plan. Benefits include improved fasting plasma glucose, reduced post‑prandial glucose spikes, and a lower risk of hyperglycaemic episodes. Because the tablet is taken once daily with the evening meal, patient convenience is enhanced, which can improve long‑term adherence. Additionally, the sustained‑release design may reduce the incidence of gastrointestinal side effects commonly associated with immediate‑release metformin.

How It Works

Metformin exerts its glucose‑lowering effect through multiple pathways: it suppresses gluconeogenesis in the liver, decreases intestinal absorption of glucose, and increases peripheral insulin sensitivity. Glimepiride, a sulfonylurea, binds to the ATP‑sensitive potassium channels on pancreatic beta‑cells, leading to depolarisation and subsequent insulin release. The synergistic action of these two agents results in a dual approach — reducing hepatic glucose output while simultaneously enhancing insulin secretion. This combined mechanism addresses both insulin resistance and beta‑cell dysfunction, two central pathogenic factors in Type 2 diabetes. The sustained‑release technology ensures that both components are released gradually, providing a more stable therapeutic profile and minimizing peak‑related side effects.

Dosage Guidelines

Dosage of Glycomet GP 2 must be individualized based on the patient’s renal function, glycaemic status, and response to therapy. The typical starting dose is one tablet taken once daily with the evening meal. If additional glycaemic control is required, the physician may increase the dose up to a maximum of two tablets per day, always respecting the maximum recommended daily dose of metformin (2 g) and glimepiride (6 mg). Dose adjustments are recommended in patients with impaired renal function, as metformin is primarily excreted unchanged by the kidneys. It is essential that patients undergo regular monitoring of blood glucose and, where appropriate, renal function tests to guide dose modifications. The medication should be taken exactly as prescribed; altering the dose without medical supervision can increase the risk of hypoglycaemia or inadequate glucose control.

Side Effects

Like all pharmaceutical products, Glycomet GP 2 may cause adverse effects. The most frequently reported side effects include gastrointestinal disturbances such as nausea, diarrhoea, abdominal discomfort, and a metallic taste. Some patients may experience mild dizziness or headache. Although rare, more serious adverse events can occur, including lactic acidosis associated with metformin accumulation, particularly in individuals with compromised renal function, severe hepatic impairment, or uncontrolled heart failure. Hypoglycaemia is a potential risk when glimepiride is used in combination with other glucose‑lowering agents or in patients with irregular eating patterns. Patients should be advised to report persistent or worsening side effects to their healthcare provider promptly. For a comprehensive list of side effects, refer to the official prescribing information.

Warnings and Precautions

Before initiating therapy with Glycomet GP 2, clinicians should assess renal function, hepatic status, and cardiovascular health. The medication is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, or known hypersensitivity to metformin or sulfonylureas. Caution is advised in elderly patients, who may be more susceptible to hypoglycaemia and renal function decline. Concomitant use of other drugs that affect renal perfusion (e.g., NSAIDs, diuretics) should be monitored closely. Patients should be instructed to maintain adequate hydration and to avoid excessive alcohol consumption, which can increase the risk of lactic acidosis. Regular laboratory monitoring, including renal function and electrolytes, is recommended during treatment. For detailed safety information, consult the FDA‑approved label or reputable sources such as the National Institutes of Health (NIH) diabetes resources (NIH Diabetes Information).

Frequently Asked Questions

1. What is the difference between Glycomet GP 2 and a single‑ingredient metformin tablet?
   Glycomet GP 2 combines metformin with glimepiride, offering dual mechanisms of action that target both hepatic glucose production and pancreatic insulin secretion. This combination can achieve greater HbA1c reductions in patients who do not respond adequately to metformin alone.
2. Can Glycomet GP 2 be taken with other diabetes medications?
   It is generally not recommended to combine Glycomet GP 2 with other sulfonylureas or insulin secretagogues due to an increased risk of hypoglycaemia. However, it may be used alongside metformin monotherapy or certain GLP‑1 receptor agonists under medical supervision.
3. How should the sustained‑release tablets be stored?
   Store the tablets at room temperature, away from moisture and direct sunlight. Keep the strip sealed until ready to use, and do not transfer the tablets to another container.
4. Is Glycomet GP 2 safe for patients with kidney disease?
   Metformin is cleared renally; therefore, patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² should avoid this medication. Dose reduction or alternative therapy may be required for those with mild to moderate renal impairment.
5. Where can I find the full prescribing information for Glycomet GP 2?
   Detailed prescribing information is available on the manufacturer’s website and through regulatory agencies such as the FDA. Reliable sources also include the MedlinePlus database (MedlinePlus Diabetes) and the official USV product label.

Related Products

• Erytop Gel (Clindamycin)
• Okamet 500 Mg (Metformin)
• Angispan TR (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 2.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 6.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)
• Glycomet-GP 1 Tablet (Metformin/Glimepiride)
• Amaryl M 1mg (Metformin/Glimepiride)